> 2010 Publications
1. Prostate Cancer Risk Allele Specific for African Descent Correlates with Pathologic Stage at Prostatectomy.
Whitman EJ, Pomerantz M, Chen Y, Chamberlin MM, Furusato B, Gao C, Ali A, Ravindranath L, Dobi A, Sesterhenn IA, McLeod DG, Srivastava S, Freedman M, Petrovics G.
Cancer Epidemiology, Biomarkers, & Prevention, 1:1-8, 2010.
Abstract
2. A FOXA1-binding Enhancer Regulates Hoxb13 Expression in the Prostate Gland.
McMullin RP, Dobi A, Mutton LN, Orosz A, Maheshwari S, Shashikant C, Bieberich CJ.
Proc. Natl. Acad. Sci., USA, 107:98-103, 2009.
Abstract
3. Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor
Cells Reflects TMPRSS2–ERG Fusion Status.
K Mwamukonda, Y Chen, L Ravindranath, B Furusato, Y Hu, J Sterbis, D Osborn, I Rosner,
IA Sesterhenn, DG McLeod, S Srivastava, G Petrovics
Prostate Cancer and Prostatic Diseases, (2010) 13, 47–51.
Abstract
4. Evaluation of the ETS-Related Gene mRNA in Urine
for the Detection of Prostate Cancer.
Kevin R. Rice, Yongmei Chen, Amina Ali, Eric J. Whitman, Amy Blase, Mona Ibrahim, Sally Elsamanoudi,
Stephen Brassell, Bungo Furusato, Norbert Stingle, Isabell A. Sesterhenn, Gyorgy Petrovics,
Siobhan Miick, Harry Rittenhouse, Jack Groskopf, David G. McLeod, and Shiv Srivastava
Clin Cancer Res; 16(5) March 1, 2010.
Abstract
5. Prostate Cancer in Men Less Than the Age of 50: A Comparison of Race and Outcomes.
Parker PM, Rice KR, Sterbis JR, Chen Y, Cullen J, McLeod DG, Brassell SA
Urology; 2011 Mar 11. [Epub ahead of print].
Abstract
6. ERG expression levels in prostate tumors reflect functional status of the androgen receptor (AR) as a consequence of fusion of ERG with AR regulated gene promoters.
Dobi A, Furusato B, Shaheduzzaman S, Chen Y, Vahey M, Nydam T, Sesterhenn IA, McLeod DG, Petrovics G, Srivastava S
The Open Cancer Journal; 2010, 3, 101-108.
7. ERG oncoprotein expression in prostate cancer: clonoal progression of ERG-positive tumor cells and potential for ERG-based stratification.
Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA
Prostate Cancer Prostatic Dis; 2010 Sep;13(3):228-37.
Abstract
8. Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors.
Ali A, Furusato B, Ts'o PO, Lum ZP, Elsamanoudi S, Mohamed A, Srivastava S, Moul JW, Brassell SA, Sesterhenn IA, McLeod DG
A Pathol Int; 2010 Oct; 60(10):667-72. doi: 10.1111/j.14440-1827.2010.02584.x.
Abstract
9. Prostate cancer in Asian Americans: incidence, management and outcomes in an equal access healthcare system.
Raymundo EM, Rice KR, Chen Y, Zhao J, Brassell SA
BJU Int; agement and outcomes in an equal access healthcare system. BJU Int. 2010 Oct 29. doi: 10.1111/j. 1464-410X.2010.09685.X. [epub ahead of print]
Abstract
10. Ets family protein. erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody.
Mohamed AA, Tan SH, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ, Sesterhenn IA, Dobi A, Srivastava S, Sreenath TL
J Cancer; 2010 Oct 25;1:197-208.
Abstract
11. Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic.
Rice K, Hudak J, Peay K, Elsamanoudi S, Travis J, Lockhart R, Cullen J, Black L, Houge S, Brassell S
Urology; 2010 Nov; 76(5):1231-8.
Abstract
12. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.
Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):311-5.
Abstract
